Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Clinical & Experimental Metastasis
Published in: Clinical & Experimental Metastasis 4/2010

01-04-2010 | Research Paper

GPR56 Plays varying roles in endogenous cancer progression

Authors: Lei Xu, Shahinoor Begum, Marc Barry, Denise Crowley, Liquan Yang, Roderick T. Bronson, Richard O. Hynes

Published in: Clinical & Experimental Metastasis | Issue 4/2010

Login to get access

Abstract

GPR56, a non-classical adhesion receptor, was previously reported to suppress tumor growth and metastasis in xenograft models using human melanoma cell lines. To understand whether GPR56 plays similar roles in the development of endogenous tumors, we analyzed cancer progression in Gpr56 −/− mice using a variety of transgenic cancer models. Our results showed that GPR56 suppressed prostate cancer progression in the TRAMP model on a mixed genetic background, similar to its roles in progression of melanoma xenografts. However, its roles in other cancer types appeared to be complex. It had marginal effects on tumor onset of mammary tumors in the MMTV–PyMT model, but had no effects on subsequent tumor progression in either the MMTV–PyMT mice or the melanoma model, Ink4a/Arf −/− tyr-Hras. These results indicate diverse roles of GPR56 in cancer progression and provide the first genetic evidence for the involvement of an adhesion GPCR in endogenous cancer development.
Appendix
Available only for authorised users
Literature
1.
Morgan MR, Humphries MJ, Bass MD (2007) Synergistic control of cell adhesion by integrins and syndecans. Nat Rev Mol Cell Biol 8(12):957–969CrossRefPubMed
2.
3.
Miranti CK, Brugge JS (2002) Sensing the environment: a historical perspective on integrin signal transduction. Nat Cell Biol 4(4):E83–E90CrossRefPubMed
4.
Streuli CH, Akhtar N (2009) Signal co-operation between integrins and other receptor systems. Biochem J 418(3):491–506CrossRefPubMed
5.
Lagerstrom MC, Schioth HB (2008) Structural diversity of G protein-coupled receptors and significance for drug discovery. Nat Rev Drug Discov 7(4):339–357CrossRefPubMed
6.
Stacey M, Chang GW, Davies JQ et al (2003) The epidermal growth factor-like domains of the human EMR2 receptor mediate cell attachment through chondroitin sulfate glycosaminoglycans. Blood 102(8):2916–2924CrossRefPubMed
7.
Kwakkenbos MJ, Pouwels W, Matmati M et al (2005) Expression of the largest CD97 and EMR2 isoforms on leukocytes facilitates a specific interaction with chondroitin sulfate on B cells. J Leukoc Biol 77(1):112–119PubMed
8.
Xu L, Begum S, Hearn JD et al (2006) GPR56, an atypical G protein-coupled receptor, binds tissue transglutaminase, TG2, and inhibits melanoma tumor growth and metastasis. Proc Natl Acad Sci USA 103(24):9023–9028CrossRefPubMed
9.
Wang T, Ward Y, Tian L et al (2005) CD97, an adhesion receptor on inflammatory cells, stimulates angiogenesis through binding integrin counterreceptors on endothelial cells. Blood 105(7):2836–2844CrossRefPubMed
10.
Vallon M, Essler M (2006) Proteolytically processed soluble tumor endothelial marker (TEM) 5 mediates endothelial cell survival during angiogenesis by linking integrin alpha(v)beta3 to glycosaminoglycans. J Biol Chem 281(45):34179–34188CrossRefPubMed
11.
Lorand L, Graham RM (2003) Transglutaminases: crosslinking enzymes with pleiotropic functions. Nat Rev Mol Cell Biol 4(2):140–156CrossRefPubMed
12.
Xu L, Hynes RO (2007) GPR56 and TG2: possible roles in suppression of tumor growth by the microenvironment. Cell Cycle 6(2):160–165PubMed
13.
Li S, Jin Z, Koirala S et al (2008) GPR56 regulates pial basement membrane integrity and cortical lamination. J Neurosci 28(22):5817–5826CrossRefPubMed
14.
Koirala S, Jin Z, Piao X et al (2009) GPR56-regulated granule cell adhesion is essential for rostral cerebellar development. J Neurosci 29(23):7439–7449CrossRefPubMed
15.
Zendman AJ, Cornelissen IM, Weidle UH et al (1999) TM7XN1, a novel human EGF-TM7-like cDNA, detected with mRNA differential display using human melanoma cell lines with different metastatic potential. FEBS Lett 446(2–3):292–298CrossRefPubMed
16.
Shashidhar S, Lorente G, Nagavarapu U et al (2005) GPR56 is a GPCR that is overexpressed in gliomas and functions in tumor cell adhesion. Oncogene 24(10):1673–1682CrossRefPubMed
17.
Sud N, Sharma R, Ray R et al (2006) Differential expression of G-protein coupled receptor 56 in human esophageal squamous cell carcinoma. Cancer Lett 233(2):265–270CrossRefPubMed
18.
19.
Greenberg NM, DeMayo F, Finegold MJ et al (1995) Prostate cancer in a transgenic mouse. Proc Natl Acad Sci USA 92(8):3439–3443CrossRefPubMed
20.
Lin EY, Jones JG, Li P et al (2003) Progression to malignancy in the polyoma middle T oncoprotein mouse breast cancer model provides a reliable model for human diseases. Am J Pathol 163(5):2113–2126PubMed
21.
Chin L, Pomerantz J, Polsky D et al (1997) Cooperative effects of INK4a and ras in melanoma susceptibility in vivo. Genes Dev 11(21):2822–2834CrossRefPubMed
22.
Kaplan-Lefko PJ, Chen TM, Ittmann MM et al (2003) Pathobiology of autochthonous prostate cancer in a pre-clinical transgenic mouse model. Prostate 55(3):219–237CrossRefPubMed
23.
Wong SY, Haack H, Kissil JL et al (2007) Protein 4.1B suppresses prostate cancer progression and metastasis. Proc Natl Acad Sci USA 104(31):12784–12789CrossRefPubMed
24.
Gingrich JR, Barrios RJ, Morton RA et al (1996) Metastatic prostate cancer in a transgenic mouse. Cancer Res 56(18):4096–4102PubMed
25.
Hurwitz AA, Foster BA, Allison JP, et al (2001) The TRAMP mouse as a model for prostate cancer. Curr Protoc Immunol, Chap. 20: Unit 20 5
26.
27.
Galle J, Aust G, Schaller G et al (2006) Individual cell-based models of the spatial-temporal organization of multicellular systems–achievements and limitations. Cytometry A 69(7):704–710PubMed
28.
Nishimori H, Shiratsuchi T, Urano T et al (1997) A novel brain-specific p53-target gene, BAI1, containing thrombospondin type 1 repeats inhibits experimental angiogenesis. Oncogene 15(18):2145–2150CrossRefPubMed
29.
Terskikh AV, Easterday MC, Li L et al (2001) From hematopoiesis to neuropoiesis: evidence of overlapping genetic programs. Proc Natl Acad Sci USA 98(14):7934–7939CrossRefPubMed
30.
Terskikh AV, Miyamoto T, Chang C et al (2003) Gene expression analysis of purified hematopoietic stem cells and committed progenitors. Blood 102(1):94–101CrossRefPubMed
31.
Akimov SS, Krylov D, Fleischman LF et al (2000) Tissue transglutaminase is an integrin-binding adhesion coreceptor for fibronectin. J Cell Biol 148(4):825–838CrossRefPubMed
32.
Akimov SS, Belkin AM (2001) Cell surface tissue transglutaminase is involved in adhesion and migration of monocytic cells on fibronectin. Blood 98(5):1567–1576CrossRefPubMed
33.
Iguchi T, Sakata K, Yoshizaki K et al (2008) Orphan G protein-coupled receptor GPR56 regulates neural progenitor cell migration via a G alpha 12/13 and Rho pathway. J Biol Chem 283(21):14469–14478CrossRefPubMed
34.
Metadata
Title
GPR56 Plays varying roles in endogenous cancer progression
Authors
Lei Xu
Shahinoor Begum
Marc Barry
Denise Crowley
Liquan Yang
Roderick T. Bronson
Richard O. Hynes
Publication date
01-04-2010
Publisher
Springer Netherlands
Published in
Clinical & Experimental Metastasis / Issue 4/2010
Print ISSN: 0262-0898
Electronic ISSN: 1573-7276
DOI
https://doi.org/10.1007/s10585-010-9322-3

Other articles of this Issue 4/2010

Clinical & Experimental Metastasis 4/2010 Go to the issue

Research Paper

Targeting activated integrin αvβ3 with patient-derived antibodies impacts late-stage multiorgan metastasis

Research Paper

Small breast epithelial mucin (SBEM) has the potential to be a marker for predicting hematogenous micrometastasis and response to neoadjuvant chemotherapy in breast cancer

Research Paper

Potentiation of cell invasion and matrix metalloproteinase production by α3β1 integrin-mediated adhesion of gastric carcinoma cells to laminin-5

Research Paper

RANK-Fc inhibits malignancy via inhibiting ERK activation and evoking caspase-3-mediated anoikis in human osteosarcoma cells

Research Paper

Oligometastases confined one organ from colorectal cancer treated by SBRT

Research Paper

A sensitive polymerase chain reaction-based method for detection and quantification of metastasis in human xenograft mouse models
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits